

SHORT REPORT

Open Access

Hyperimmune intravenous immunoglobulin containing high titers of pandemic H1N1 hemagglutinin and neuraminidase antibodies provides dose-dependent protection against lethal virus challenge in SCID mice

Christine Hohenadl¹, Walter Wodal¹, Astrid Kerschbaum¹, Richard Fritz¹, M Keith Howard¹, Maria R Farcet², Daniel Portsmouth¹, John K McVey³, Donald A Baker³, Hartmut J Ehrlich⁴, P Noel Barrett¹ and Thomas R Kreil^{2*}

Abstract

Background: Convalescent plasma and fractionated immunoglobulins have been suggested as prophylactic or therapeutic interventions during an influenza pandemic.

Findings: Intravenous immunoglobulin (IVIG) preparations manufactured from human plasma collected before the 2009 H1N1 influenza pandemic, and post-pandemic hyperimmune (H)-IVIG preparations were characterized with respect to hemagglutination inhibition (HI), microneutralization (MN) and neuraminidase-inhibiting (NAI) antibody titers against pandemic H1N1 (pH1N1) and seasonal H1N1 (sH1N1) viruses. The protective efficacy of the IVIG and H-IVIG preparations was evaluated in a SCID mouse challenge model.

Substantial levels of HI, MN and NAI antibodies against pH1N1 (GMTs 1:45, 1:204 and 1:727, respectively) and sH1N1 (GMTs 1:688, 1:4,946 and 1:312, respectively) were present in pre-pandemic IVIG preparations. In post-pandemic H-IVIG preparations, HI, MN and NAI antibody GMTs against pH1N1 were 1:1,280, 1:11,404 and 1:2,488 (28-, 56- and 3.4-fold enriched), respectively, compared to pre-pandemic IVIG preparations ($p < 0.001$). Post-pandemic H-IVIG (HI titer 1:1,280) provided complete protection from lethality of SCID mice against pH1N1 challenge (100% of mice survived for 29 days post-challenge). Pre-pandemic IVIG (HI titer 1:70) did not provide significant protection against pH1N1 challenge (50% of mice survived 29 days post-challenge compared to 40% survival in the buffer control group). There was a highly significant correlation between circulating *in vivo* HI and MN antibody titers and survival ($p < 0.001$).

Conclusion: The substantial enrichment of HA- and NA-specific antibodies in H-IVIG and the efficacious protection of SCID mice against challenge with pH1N1 suggests H-IVIG as a promising intervention against pandemic influenza for immunocompromised patients and other risk groups.

Keywords: H1N1, IVIG, Influenza, Intravenous immunoglobulin, Passive transfer, Neutralizing antibody, Neuraminidase, Hemagglutinin

* Correspondence: thomas_kreil@baxter.com

²Global Pathogen Safety, Baxter BioScience, Benatzkygasse 2-6, 1221 Vienna, Austria

Full list of author information is available at the end of the article

Background

Infectious diseases were commonly managed by passive transfer of human or animal sera prior to the development of effective vaccines and antimicrobials, and passive transfer of convalescent sera is currently still used to prevent and treat some viral and bacterial infections [1,2]. The use of convalescent plasma and fractionated immunoglobulins [3,4], and, more recently, monoclonal antibodies [5-8], has been suggested as a complementary strategy to prevent or treat virus infection during an influenza pandemic. Treatment of severe pH1N1 infection with convalescent plasma or H-IVIG was associated with lower viral load and reduced mortality [9,10].

As previously reported [11], we investigated the feasibility of manufacturing H-IVIG as a response to the emergence of the 2009 H1N1 pandemic (pH1N1) virus. H-IVIG preparations were shown to have significantly elevated levels of pH1N1 hemagglutinating (HI) and neutralizing antibodies, as assessed by microneutralization (MN) assay, compared to standard IVIG preparations collected from donors either during or before the H1N1 pandemic [11].

In the present study, we further characterized post-pandemic H-IVIG preparations with respect to HI and MN antibodies against both pH1N1 and a seasonal H1N1 (sH1N1) virus (A/New Caledonia/20/1999, which circulated in the Northern hemisphere and was a recommended component of the trivalent seasonal vaccine from 2000–01 to 2006–07). We also assessed the level of pre-existing cross-reactive pH1N1 immunity in the donor population by determining the HI and MN titers against pH1N1 and sH1N1 in pre-pandemic IVIG preparations. In addition, we investigated the extent to which antibodies capable of inhibiting the enzymatic activity of the sH1N1 and pH1N1 neuraminidase (NA) antigens were enriched in the post-pandemic compared to pre-pandemic preparations. We also investigated the ability of pre-pandemic IVIG and post-pandemic H-IVIG to protect highly susceptible immunodeficient SCID mice against challenge with wild-type pH1N1 virus.

Methods

IVIG and H-IVIG

A total of 13 IVIG preparations (Gammagard Liquid/KIOVIG, Baxter Healthcare, Westlake Village, CA) manufactured from human plasma collected before the 2009 H1N1 influenza pandemic (manufactured January to November 2009, plasma collected >6 months prior to these dates), and two lots of post-pandemic H-IVIG preparations (manufactured July 2010) [11] were characterized in the present study. For IVIG production, collected plasma was pooled into two 7500-L batches, and the Cohn ethanol fractionation and downstream processes for the two H-IVIG lots were performed in full accordance with the licensed process for Gammagard

Liquid/KIOVIG, a triple virus-reduced 10% IVIG preparation [12,13].

Laboratory Assays

Pre-pandemic IVIG and H-IVIG preparations were characterized with respect to HI and MN titers against pH1N1 (A/California/07/2009 reassortant NYMC X-179A), and sH1N1 (A/New Caledonia/20/1999), as previously described [11].

Antibodies capable of inhibiting the enzymatic activity of NA (NAi antibodies) in the IVIG and H-IVIG preparations were detected using a highly sensitive enzyme-linked lectin assay (ELLA), as previously described [14]. N1 antigens were obtained by splitting wild-type A/California/07/2009 (CDC, Atlanta, GA) and A/New Caledonia/20/1999 virus preparations by overnight incubation with 0.5% Triton X-100 at 4°C, followed by detergent removal using 20% Bio-Beads (Biorad).

Mouse passive transfer studies

6–8 week old SCID mice (strain CBI7/Icr-Prkdcscid/IcrCrl; Charles River Laboratories, Germany) were intranasally infected with 30 µl containing 6×10^4 tissue culture infectious dose 50% (TCID₅₀) of H1N1 strain A/California/07/2009 (9.5-fold 50% lethal (LD₅₀) dose [15]) and monitored 29 days. For passive protection studies, mice were intraperitoneally injected three days prior to challenge with 200 µl of H-IVIG, IVIG or PBS control. Two independent experiments with two different lots of H-IVIG (8–10 mice per group), and two independent experiments with a pool of 5 lots of IVIG or PBS control (10 mice per group) were done. For calculation of dose-dependency, 200 µl of undiluted and 2-fold serial dilutions of H-IVIG, undiluted IVIG or phosphate-buffered saline (PBS) were used. Serum was obtained from animals before challenge, at Day 3, and at Day 32 to determine circulating *in vivo* antibody titers.

Statistical analysis

Statistical differences between IVIG and H-IVIG antibody titers were calculated from combined data by unpaired Student t-test analysis. Differences in survival were analyzed with a Log-rank (Mantel-Cox) test. The significance of the correlation of *in vitro* and *in vivo* HI and MN titers, as determined on Day 3 and Day 32, as well as correlation of Day 3 antibody titers with survival was evaluated using a nonparametric Spearman correlation analysis (GraphPad Prism v.5.01 software).

Results and Discussion

To investigate the titers of antibodies against sH1N1 and pH1N1 in pre-pandemic (n = 13) and post-pandemic IVIG (n = 2) preparations, sera were analyzed by HI, MN and NAi assays. Figure 1 shows HI, MN and NAi titers

measured in pre-pandemic IVIG preparations (open bars) and post-pandemic H-IVIG preparations (hatched bars). Pre-pandemic IVIG preparations had substantial HI, MN and NAi titers against pH1N1 (grey bars) (geometric mean titer [GMT] 1:45, 1:204 and 1:727, respectively), as well as against sH1N1 (white bars) (GMT 1:688, 1:4,946, and 1:312 respectively). As expected, significantly higher HI, MN and NAi antibody titers against pH1N1 were present in the post-pandemic H-IVIG preparations compared to titers in the pre-pandemic IVIG preparations ($P < 0.0001$ for all serological assays). GMTs of 1:2,560 (HI), 1:11,404 (MN) and 1: 2,488 (NAi) were determined for the post-pandemic H-IVIG preparations, an increase of 28- 56- and 3.4-fold, respectively, compared to pre-pandemic IVIG preparations. In addition, higher titers of HI (1:2,560), MN (1:16,127) and NAi (1:717) antibodies against sH1N1 were also present in the post-pandemic H-IVIG preparations.

The finding that substantial levels of HI and MN antibodies against pH1N1 were also present in the pre-pandemic IVIG preparations is in agreement with other vaccine and seroepidemiological studies which reported high rates of seroprotective pre-exposure pH1N1 HI and neutralizing antibody titers, likely as a result of cross-reactive antibodies induced by repeated exposure to seasonal H1N1 viruses [16]. The relatively low increase in pH1N1-specific NA antibody titers in H-IVIG likely reflects the high level of antigenic similarity between seasonal and pandemic H1N1 NA proteins [17].

To analyze the protective potential of pre-pandemic IVIG and post-pandemic H-IVIG preparations, passive transfer experiments were done in SCID mice. Administration of post-pandemic H-IVIG, prior to challenge with

wild-type pH1N1, provided complete protection (100% survival) of SCID mice during the 29 days monitoring period, whereas only 50% of animals receiving pre-pandemic IVIG and 40% of animals receiving buffer survived (Figure 2). Increased survival rates (compared to animals receiving pre-pandemic IVIG) afforded by post-pandemic were highly statistically significant (Mantel-Cox Log-rank $P < 0.0001$) but not for pre-pandemic IVIG compared to buffer control ($P = 0.15$). The relatively long survival time of the mice receiving buffer only is a result of the relatively low pathogenicity of the pH1N1 virus in mice [18,19]. Due to constraints of the challenge volume used, it was however not possible to increase the challenge dose.

To investigate the extent to which protection against pH1N1 challenge by H-IVIG administration is dose-dependent, mice were administered with serial 2-fold dilutions of H-IVIG prior to challenge with pH1N1. Circulating *in vivo* HI and MN antibody titers were measured in sera taken from animals immediately prior to challenge and at the end of the experiment i.e. 29 days after virus challenge. Table 1 shows the HI and MN titers of H-IVIG preparations administered to mice, the circulating antibody titers measured at the time of challenge and 29 days after challenge, and the associated survival rates of mice challenged with pH1N1 virus. Protection was dose-dependent, and there was a highly significant correlation (nonparametric Spearman correlation $r = 0.9$, $P < 0.0001$) between circulating *in vivo* HI and MN antibody titers measured on the day of virus challenge and survival.

Although these data demonstrate the potential of H-IVIG as a potential prophylactic intervention in the




Figure 1 Serological characterization of pre-pandemic IVIG (open bars) and post-pandemic H-IVIG (hatched bars). Antibody titers against the seasonal H1N1 strain A/New Caledonia/20/1999 (sH1N1) (white bars) and pandemic A/California/07/2009 (pH1N1) (grey bars) were determined by hemagglutination inhibition (HI), microneutralization (MN) and enzyme-linked lectin assay (ELLA, reported as NA inhibition [NAi]), respectively. Results are given as geometric mean titer (GMT) \pm 95% confidence interval (CI). Statistical differences were calculated by unpaired Student t-test analysis (GraphPad Prism software). *** $P < 0.0001$. GMTs were calculated by testing 13 individual lots of IVIG and 2 lots of H-IVIG.




Figure 2 Protective efficacy of pre-pandemic IVIG and post-pandemic H-IVIG. To evaluate passive protection efficacy, SCID mice were intraperitoneally administered with 200 μ l of pH1N1 hyperimmune IVIG (two lots, HI titer 1:1,280) or pre-pandemic IVIG (pool of five lots, HI titer 1:70) 3 days prior to challenge with 6×10^4 TCID₅₀ of wild-type pH1N1 by intranasal instillation. The control group received 200 μ l of PBS and survival was monitored for 29 days. Statistical differences between the IVIG group and the PBS control group, and between the IVIG group and the H-IVIG group, were calculated with a Log-rank (Mantel-Cox) test using the GraphPad Prism software. Abbreviations: d, days; n.s., not significant; IVIG, pre-pandemic intravenous immunoglobulin; H-IVIG, hyperimmune intravenous immunoglobulin.

event of an influenza pandemic, there are several limitations to our study. In addition to showing the protective effect of H-IVIG with respect to survival of challenged animals, it would have been interesting to investigate the ability of H-IVIG to ameliorate disease symptoms (e.g. by prevention of weight loss) and to reduce viral load and cytokine levels in challenged animals. It would also have been interesting to determine whether post-pandemic H-IVIG also protects against influenza viruses of other subtypes. Several studies have reported that infection or vaccination with pH1N1 boosted broadly neutralizing HA stem antibodies in humans [20-24].

An additional limitation is that we did not investigate the potential therapeutic efficacy of H-IVIG. Several recent studies have demonstrated that post-infection administration of influenza-specific monoclonal antibodies can effectively treat mice or ferrets which were previously subjected to virus challenge [5-8]. Treatment of humans with severe pH1N1 infection with convalescent plasma or H-IVIG was also associated with lower viral load and reduced mortality [9,10]. However, prophylactic passive administration of H-IVIG could be administered to acutely immunocompromised individuals who are at high-risk of serious complications resulting from

Table 1 Antibody titers and protection

Sample (dilution)	HI GMT			MN GMT			% survival
	In vitro ^a	In vivo		In vitro ^a	In vivo		
		Day 3 ^b	Day 32 ^c		Day 3 ^b	Day 32 ^c	
H-IVIG (undiluted)	1280	163	33	3420	349	34	100
H-IVIG (1:2)	640	143	26	1710	190	15	95
H-IVIG (1:4)	320	63	14	855	95	11	90
H-IVIG (1:8)	160	35	8	428	48	6	76
H-IVIG (1:16)	80	21	6	214	24	5	63
IVIG (undiluted)	70	6	7	60	5	5	50
Buffer control	n.a.	5	5	n.a.	5	5	40

^ain vitro titer of neat samples determined prior to i.p. injection; titers of diluted H-IVIG are calculated accordingly.

^bmouse serum titers 3 days after passive transfer; i.e. at the time of challenge.

^cmouse serum titers 32 days after passive transfer; i.e. 29 days after challenge.

HI, hemagglutination inhibition; MN, microneutralization; GMT, geometric mean titer; n.a., not applicable.

Note: IVIG was a pooled preparation from 5 different IVIG lots; 2 different lots of H-IVIG were used separately. Data shown are combined data from 2 independent experiments.

influenza infection and who may not mount an effective response to vaccination, such as HIV patients, transplant recipients and cancer patients. In the event of a pandemic caused by a highly pathogenic influenza virus, passive immunization might also be considered for first-line health care workers and for direct contacts of infected individuals.

Conclusion

Taken together, the data in this study demonstrating substantial enrichment of HA- and NA-specific antibodies in H-IVIG and the efficacious protection of SCID mice against challenge with pH1N1 indicate that H-IVIG could be used as a prophylactic intervention against pandemic influenza for immunocompromised patients and other risk groups.

Competing interests

All authors are employees of Baxter BioScience, manufacturer of the pandemic H1N1 hyperimmune intravenous immunoglobulin. WW, AK, MKH, JKMcV, DAB, HJE, PNB and TRK have stock options. The study was funded by Baxter BioScience.

Authors' contributions

CH, WW, MKH, JKM, DAB and TRK conceived and planned the study. CH, WW, AK, RF and MRF collected the data. All authors were involved in data analysis and drafting and revision of the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We would like to thank Claudia Stanislav, Isabella Strini and Ernst Waeger for performing HI and MN analysis, and Nicole Hetzelt and Chery Abraham for conducting the ELLA.

Author details

¹Vaccine R&D, Baxter BioScience, Orth/Donau, Austria. ²Global Pathogen Safety, Baxter BioScience, Benatzkygasse 2-6, 1221 Vienna, Austria. ³Global Quality, Baxter BioScience, Deerfield, Illinois, USA. ⁴Global R&D, Baxter BioScience, 1220 Vienna, Austria.

Received: 24 January 2014 Accepted: 7 April 2014

Published: 16 April 2014

References

1. Luke TC, Casadevall A, Watowich SJ, Hoffman SL, Beigel JH, Burgess TH: **Hark back: passive immunotherapy for influenza and other serious infections.** *Crit Care Med* 2010, **38**:e66–e73.
2. Keller MA, Stiehm ER: **Passive immunity in prevention and treatment of infectious diseases.** *Clin Microbiol Rev* 2000, **13**:602–614.
3. World Health Organization: *WHO Blood Regulators Network - Position Paper on collection and Use of Convalescent Plasma or Serum as an Element in Pandemic Influenza Planning.* Geneva, Switzerland: WHO; 2009:1–4. www.who.int/bloodproducts/brn/BRNPosition-ConvPlasma10July09.pdf.
4. Leider JP, Brunker PA, Ness PM: **Convalescent transfusion for pandemic influenza: preparing blood banks for a new plasma product?** *Transfusion* 2010, **50**:1384–1398.
5. Friesen RH, Koudstaal W, Koldijk MH, Weverling GJ, Brakenhoff JP, Lenting PJ, Stittelaar KJ, Osterhaus AD, Kompier R, Goudsmit J: **New class of monoclonal antibodies against severe influenza: prophylactic and therapeutic efficacy in ferrets.** *PLoS One* 2010, **5**:e9106.
6. Nguyen HH, Tumpey TM, Park HJ, Byun YH, Tran LD, Nguyen VD, Kilgore PE, Czerkinsky C, Katz JM, Seong BL, Song JM, Kim YB, Do HT, Nguyen T, Nguyen CV: **Prophylactic and therapeutic efficacy of avian antibodies against influenza virus H5N1 and H1N1 in mice.** *PLoS One* 2010, **5**:e10152.
7. Prabhu N, Prabhakaran M, Hongliang Q, He F, Ho HT, Qiang J, Goutama M, Lim AP, Hanson BJ, Kwang J: **Prophylactic and therapeutic efficacy of a chimeric monoclonal antibody specific for H5 haemagglutinin against lethal H5N1 influenza.** *Antivir Ther* 2009, **14**:911–921.
8. Simmons CP, Bernasconi NL, Suguitan AL, Mills K, Ward JM, Chau NV, Hien TT, Sallusto F, Ha DQ, Farrar J, De J, Lanzavecchia A, Subbarao K: **Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza.** *PLoS Med* 2007, **4**:e178.
9. Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, Liu R, Watt CL, Chan WM, Lai KY, Koo CK, Buckley T, Chow FL, Wong KK, Chan HS, Ching CK, Tang BS, Lau CC, Li IW, Liu SH, Chan KH, Lin CK, Yuen KY: **Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection.** *Clin Infect Dis* 2011, **52**:447–456.
10. Hung IF, To KK, Lee CK, Lee KL, Yan WW, Chan K, Chan WM, Ngai CW, Law KI, Chow FL, Liu R, Lai KY, Lau CC, Liu SH, Chan KH, Lin CK, Yuen KY: **Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A (H1N1) infection.** *Chest* 2013, **144**:464–473.
11. Kreil TR, Mc Vey JK, Lei LS, Camacho L, Wodal W, Kerschbaum A, Segura E, Vandamme E, Gavit P, Ehrlich HJ, Barrett PN, Baker DA: **Preparation of commercial quantities of a hyperimmune human intravenous immunoglobulin preparation against an emerging infectious disease: the example of pandemic H1N1 influenza.** *Transfusion* 2012, **52**:803–809.
12. Poelsler G, Berting A, Kindermann J, Spruth M, Hammerle T, Teschner W, Schwarz HP, Kreil TR: **A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity.** *Vox Sang* 2008, **94**:184–192.
13. Teschner W, Butterweck HA, Auer W, Muchitsch EM, Weber A, Liu SL, Wah PS, Schwarz HP: **A new liquid, intravenous immunoglobulin product (IGIV 10%) highly purified by a state-of-the-art process.** *Vox Sang* 2007, **92**:42–55.
14. Fritz R, Sabarth N, Kiermayr S, Hohenadl C, Howard MK, Ilk R, Kistner O, Ehrlich HJ, Barrett PN, Kreil TR: **A vero cell-derived whole-virus H5N1 vaccine effectively induces neuraminidase-inhibiting antibodies.** *J Infect Dis* 2012, **205**:28–34.
15. Kistner O, Crowe BA, Wodal W, Kerschbaum A, Savidis-Dacho H, Sabarth N, Falkner FG, Mayerhofer I, Mundt W, Reiter M, Grillberger L, Tauer C, Graninger M, Sachslehner A, Schwendinger M, Bruhl P, Kreil TR, Ehrlich HJ, Barrett PN: **A whole virus pandemic influenza H1N1 vaccine is highly immunogenic and protective in active immunization and passive protection mouse models.** *PLoS One* 2010, **5**:e9349.
16. Broberg E, Nicoll A, Mato-Gauci A: **Seroprevalence to influenza A(H1N1) 2009 virus—where are we?** *Clin Vaccine Immunol* 2011, **18**:1205–1212.
17. Marcelin G, DuBois R, Rubrum A, Russell CJ, McElhaney JE, Webby RJ: **A contributing role for anti-neuraminidase antibodies on immunity to pandemic H1N1 2009 influenza A virus.** *PLoS One* 2011, **6**:e26335.
18. Belsler JA, Wadford DA, Pappas C, Gustin KM, Maines TR, Pearce MB, Zeng H, Swayne DE, Pantin-Jackwood M, Katz JM, Tumpey TM: **Pathogenesis of pandemic influenza A (H1N1) and triple-reassortant swine influenza A (H1) viruses in mice.** *J Virol* 2010, **84**:4194–4203.
19. Kalthoff D, Grund C, Harder TC, Lange E, Vahlenkamp TW, Mettenleiter TC, Beer M: **Limited susceptibility of chickens, turkeys, and mice to pandemic (H1N1) 2009 virus.** *Emerg Infect Dis* 2010, **16**:703–705.
20. Li GM, Chiu C, Wrammert J, McCausland M, Andrews SF, Zheng NY, Lee JH, Huang M, Qu X, Edupuganti S, Mulligan M, Das SR, Yewdell JW, Mehta AK, Wilson PC, Ahmed R: **Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells.** *Proc Natl Acad Sci U S A* 2012, **109**:9047–9052.
21. Miller MS, Tsibane T, Krammer F, Hai R, Rahmat S, Basler CF, Palese P: **1976 and, H1N1 influenza virus vaccines boost anti-hemagglutinin stalk antibodies in humans.** *J Infect Dis* 2009, **201**(207):98–105.
22. Qiu C, Huang Y, Wang Q, Tian D, Zhang W, Hu Y, Yuan Z, Zhang X, Xu J: **Boosting heterosubtypic neutralization antibodies in recipients of 2009 pandemic H1N1 influenza vaccine.** *Clin Infect Dis* 2012, **54**:17–24.
23. Sangster MY, Baer J, Santiago FW, Fitzgerald T, Ilyushina NA, Sundararajan A, Henn AD, Krammer F, Yang H, Luke CJ, Zand MS, Wright PF, Treanor JJ, Topham DJ, Subbarao K: **B cell response and hemagglutinin stalk-reactive antibody production in different age cohorts following**

2009 H1N1 influenza virus vaccination. *Clin Vaccine Immunol* 2009, **2013** (20):867–876.

24. Wrammert J, Koutsouanos D, Li GM, Edupuganti S, Sui J, Morrissey M, McCausland M, Skountzou I, Hornig M, Lipkin WI, Mehta A, Razavi B, Del RC, Zheng NY, Lee JH, Huang M, Ali Z, Kaur K, Andrews S, Amara RR, Wang Y, Das SR, O'Donnell CD, Yewdell JW, Subbarao K, Marasco WA, Mulligan MJ, Compans R, Ahmed R, Wilson PC: **Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection.** *J Exp Med* 2011, **208**:181–193.

doi:10.1186/1743-422X-11-70

Cite this article as: Hohenadl *et al.*: Hyperimmune intravenous immunoglobulin containing high titers of pandemic H1N1 hemagglutinin and neuraminidase antibodies provides dose-dependent protection against lethal virus challenge in SCID mice. *Virology Journal* 2014 **11**:70.

**Submit your next manuscript to BioMed Central
and take full advantage of:**

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

